Clinical Trial Detail

NCT ID NCT03737955
Title Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin

Age Groups: child adult senior

No variant requirements are available.